Introduction. Dyslipidemia is the most important modifiable risk factor that leads to cardiovascular diseases. The screening for dyslipidemia in Palestine is not established in primary health care centers for healthy people. Our study aims to determine the prevalence of dyslipidemia among healthy undiagnosed adult men in Palestine in order to assess the need for screening and preventive programs for dyslipidemia. Materials and Methods. A cross-sectional observational study was carried out in 10 secondary schools at Nablus municipality (Palestine) from August 2017 to February 2018. The study included 140 teachers based on sample calculations. The age of participants ranged between 24 and 60 years. A questionnaire was used to collect demographic data about the lifestyle, past medical, and family histories. Serum lipid profile, and fasting blood glucose levels for each participant were measured. Lipoprotein levels were categorized based on the adult treatment panel III criteria. Results. The overall prevalence of dyslipidemia among Palestinian men was 66.4%. The most prevalent type of dyslipidemia was hypo HDL ( < 40 mg/dl, 59.3%), followed by hypertriglyceridemia ( ≥ 200 mg/dl, 20%). The prevalence of hyper LDL ( ≥ 160 mg/dl), hypercholesterolemia ( ≥ 240 mg/dl) was 8.5%, and 3.6%, respectively. About 15% of participants had glucose intolerance, and 4.3% had hyperglycemia (undiagnosed). Those with glucose intolerance, 13 (9.2%) have hypo HDL, while 9 (6.42%) have hypertriglyceridemia. On the other hand, out of hyperglycemic patients: 5 (3.5%) had hypo HDL, and 1 (0.7%) had hypertriglyceridemia. Conclusion. Around two-thirds of undiagnosed participants had at least one lipid abnormality. None of them were aware of having dyslipidemia. The prevalence of undiagnosed dyslipidemia was higher than the prevalence of undiagnosed glucose intolerance, and diabetes. This suggests that dyslipidemia plays a major role in developing diabetes. Hence, profound efforts should be done to manage and treat those with dyslipidemia, in order to prevent progression to type II diabetes mellitus.